Condition
CNS Disease
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Terminated2
Completed1
Withdrawn1
Unknown1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04775784Unknown
Determination of COVID-19 Related Virus in Central Nervous System
NCT04512261Phase 1Withdrawn
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
NCT04571996Phase 1CompletedPrimary
Blood-Brain Barrier Penetration of Therapeutic Agents in Human
NCT00895960Phase 1Terminated
Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
NCT00496379Phase 2Terminated
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
Showing all 5 trials